Scinai Immunotherapeutics (SCNI) Income Statement (2022 - 2023)
Income Statement report data from Mar 31, 2022 to Mar 31, 2023 for Scinai Immunotherapeutics (SCNI).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2023 | Mar 31, 2022 | |
|---|---|---|
Operating Expenses | ||
Research And Development | 2.00M (+72.41%) | 1.16M |
Selling General And Administrative | 1.19M (-17.93%) | 1.45M |
Operating Expenses | 3.19M (+21.76%) | 2.62M |
Depreciation And Amortization | 140K (+7.69%) | 130K |
Operating Income | ||
Operating Income | -3.19M (+22.22%) | -2.61M |
Ebit | -3.19M (+22.22%) | -2.61M |
EBITDA | -3.05M (+22.98%) | -2.48M |
Other Income / Expenses | ||
Other Non Operating Income | -330.00K | 140K |
Net Income | ||
Net Income From Continuing Operations | -3.51M (+42.11%) | -2.47M |
Net Income | -3.51M (+42.11%) | -2.47M |
Comprehensive Income Net Of Tax | -3.40M (+35.46%) | -2.51M |